Valuation: Impax Laboratories Inc

Market Cap 5.58B 4.89B 4.52B 4.16B 7.85B 538B 7.98B 54.09B 21.2B 263B 20.96B 20.51B 908B P/E 2026 *
47.6x
P/E 2027 * 22.1x
Enterprise Value 7.84B 6.87B 6.35B 5.84B 11.02B 756B 11.2B 75.94B 29.77B 370B 29.43B 28.79B 1,274B EV / Sales 2026 *
2.52x
EV / Sales 2027 * 2.22x
Free-Float
47.1%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2019-07-31
Chief Executive Officer 54 2019-07-31
Director of Finance/CFO 58 2023-11-06
Director TitleAgeSince
Director/Board Member 59 2023-11-06
Director/Board Member 70 2023-11-06
Director/Board Member 52 2023-11-06
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 5.69B
-2.73%-2.96%+48.62%+147.27% 1,051B
-1.67%-3.47%+52.00%+47.77% 609B
-0.44%+2.17%+33.88%+78.20% 450B
-0.75%+0.30%+28.32%+21.15% 330B
-1.52%-1.19%+33.38%+35.35% 284B
-1.70%-1.82%+20.26%+15.74% 263B
-0.58%+1.11%-20.89%-40.59% 223B
-0.58%+1.03%+23.55%+56.14% 198B
-0.80%+1.38%+23.09%+66.64% 167B
Average -0.88%-0.16%+26.91%+47.52% 397.23B
Weighted average by Cap. -0.89%-1.07%+35.25%+70.88%

Financials

2026 *2027 *
Net sales 3.12B 2.73B 2.52B 2.32B 4.38B 300B 4.45B 30.18B 11.83B 147B 11.7B 11.44B 506B 3.33B 2.92B 2.7B 2.48B 4.68B 321B 4.76B 32.25B 12.64B 157B 12.5B 12.23B 541B
Net income 122M 107M 98.79M 90.86M 171M 11.76B 174M 1.18B 463M 5.75B 458M 448M 19.82B 263M 231M 213M 196M 370M 25.38B 376M 2.55B 999M 12.42B 988M 967M 42.78B
Net Debt 2.26B 1.98B 1.83B 1.68B 3.17B 218B 3.22B 21.85B 8.57B 106B 8.47B 8.28B 367B 1.81B 1.59B 1.47B 1.35B 2.55B 175B 2.59B 17.57B 6.89B 85.55B 6.81B 6.66B 295B
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-